Rodman & Renshaw Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Emergent BioSolutions with a Buy rating and set a price target of $16.

August 22, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Emergent BioSolutions with a Buy rating and a price target of $16, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $16 by Rodman & Renshaw suggests a positive sentiment towards Emergent BioSolutions. This is likely to influence investor perception positively, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100